Resolution Bio Liquid Biopsy Outperforms Guardant Test in Lung Cancer Gene Fusion Detection

Resolution Bio Liquid Biopsy Outperforms Guardant Test in Lung Cancer Gene Fusion Detection

NEW YORK (GenomeWeb) – Researchers from the Dana-Farber Cancer Institute and Resolution Biosciences have identified more actionable gene fusion mutations with higher allele frequencies in lung cancer patients using Resolution Bioscience's ctDx-Lung liquid biopsy test than using Guardant Health's Guardant360 assay. GenomeWeb Premium gives you: Never miss another important industry story. You may already have institutional access! Already a GenomeWeb or 360Dx Premium member? *Before your trial expires, we’ll put together a custom quote with your long-term premium options.



Also in Industry News

A comprehensive analysis of evidence-based information to help manage myopia - News-Medical.Net
A comprehensive analysis of evidence-based information to help manage myopia - News-Medical.Net

0 Comments

A comprehensive analysis of evidence-based information to help manage myopia - News-Medical.Net

Read More

Applying AI to map how COVID-19 virus attacks the heart
Applying AI to map how COVID-19 virus attacks the heart

0 Comments

Applying AI to map how COVID-19 virus attacks the heart

Read More

Abnormal calcium levels in mitochondria may cause neuronal cell death in Alzheimer's disease
Abnormal calcium levels in mitochondria may cause neuronal cell death in Alzheimer's disease

0 Comments

Abnormal calcium levels in mitochondria may cause neuronal cell death in Alzheimer's disease

Read More